BUZZ-MBX Biosciences falls after executive shakeup

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00

** Shares of drug developer MBX Biosciences MBX.O fall 2.6% to $58.49 after the bell

** MBX names insider Steve Hoerter as new chief executive officer, succeeding Kent Hawryluk

** Appoints John Smither, interim finance chief since March 2026, as new chief financial officer

** All leadership changes are effective immediately

** MBX stock has nearly doubled so far this year




This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.